Title A Phase I, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SG1-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Contact ND
Principal Investigator Elizabeth Griffiths, MD
Study Number 197411
Phase1
Summary The specific purpose of th study is to find out whether SGI-110 given subcutaneously (under the skin) is safe and effective as a treatment for MDS or AML.
Eligibility
- See Clinicaltrials.gov listing for current Eligibility criteria.